Your fact-checks will appear here
American biopharmaceutical company
Neurocept’s public profile in the available sources is limited: there are no press releases or filings about a company named “Neurocept” changing a drug-development pipeline tied to Dr. Paul Alan Cox ...
Available reporting and press-distributed content show Neurocept circulating paid press releases promoting its brain-health supplement but do not present any company-issued press release or SEC filing...
Available sources do not mention a product called “Neurocept Astroncaps” and contain no international regulatory rulings specific to that name; reporting instead references Neurocrine Biosciences’ mar...
Available reporting shows that products branded Neuriva (a consumer brain‑health supplement) have been the subject of consumer class-action litigation over advertising claims, including an $8 million ...
Available sources show no regulatory filings, FDA or FTC enforcement actions, or major lawsuits specifically naming a company called “NeuroCept” (spelled that way) or its marketers in the government o...
Available filings show routine SEC reports and investor documents for Neurocrine Biosciences (ticker NBIX) — including 10‑K/10‑Q and proxy (DEF 14A) materials filed within the past two years — accessi...
Available reporting provided for review does not include any U.S. business filings for an entity named “Neurocept,” so this analysis cannot identify a registered owner or corporate officer from those ...
Available reporting does not identify any peer‑reviewed clinical trials or registered Phase 2/3 studies that test Neurocept’s product claims; existing coverage is largely promotional materials and con...
Neurocrine Biosciences’ publicly reported pipeline shows multiple candidates that reached Phase 2 or Phase 3 by mid‑2025, with mixed outcomes: at least one Phase 2 failure (NBI‑1070770 in MDD did not ...
Available reporting and filings in the provided results show multiple regulatory references to Neurocrine Biosciences in 2024 — notably FDA acceptance and approval activity tied to crinecerfont and a ...
Available reporting gives no clear, singular profile for a company named exactly “Neurocept.” The closest matches in the provided results are (a) Neuro-Bio / Neuro-Bio (a neurodegenerative biotech foc...
Neurocept has not received full FDA approval as a finished therapeutic product; publicly available analyses and fact-checks indicate and identify only device clearances for other similarly named syste...
Neurocrine Biosciences (often conflated with the name “Neurocept” in some documents) submitted clinical trial data from two pivotal Phase 3 studies, CAH3003 (adult) and CAH2006 (pediatric), to the U.S...